Publications by authors named "M Lynskey"
Background: The association between cannabis and psychosis is established, but the role of underlying genetics is unclear. We used data from the EU-GEI case-control study and UK Biobank to examine the independent and combined effect of heavy cannabis use and schizophrenia polygenic risk score (PRS) on risk for psychosis.
Methods: Genome-wide association study summary statistics from the Psychiatric Genomics Consortium and the Genomic Psychiatry Cohort were used to calculate schizophrenia and cannabis use disorder (CUD) PRS for 1098 participants from the EU-GEI study and 143600 from the UK Biobank.
Article Synopsis
- Molecular studies indicate that ALT is a crucial prognostic marker for shorter relapse-free survival (RFS) in pancreatic neuroendocrine tumors (PanNETs) and other neoplasms.
- The development of a new chromogenic ALT assay (ALT-CISH) was initiated to address clinical limitations of the traditional fluorescence in situ hybridization (FISH) method, showing a 100% agreement with FISH results in validating that ALT is present in 31% of primary PanNETs.
- The study demonstrated that ALT status is significantly associated with poorer RFS in both PanNET and leiomyosarcoma (LMS) patients, with ALT being an independent prognostic factor
Inactivating mutations in chromatin modifiers, like the α-thalassemia/mental retardation, X-linked (ATRX)-death domain-associated protein (DAXX) chromatin remodeling/histone H3.3 deposition complex, drive the cancer-specific alternative lengthening of telomeres (ALT) pathway. Prior studies revealed that HIRA, another histone H3.
View Article and Find Full Text PDFAn early economic analysis of medical cannabis for the treatment of chronic pain.
Expert Rev Pharmacoecon Outcomes Res
January 2025
Background: Cannabis-based medicinal products (CBMPs) are increasingly demonstrating effectiveness in treating a wide range of conditions, with a relatively high safety profile in clinical usage compared to other prescription pain medications and few contraindications. Consultation and other prescription-related costs are, at present, higher for CBMPs than for some other treatment options, leading to some concern around wider prescribing.
Research Design And Methods: An early cost-effectiveness model was developed to estimate the impact of prescribing CBMPs alone and/or in addition to analgesics, physiotherapy, and cognitive behavioral therapy for chronic pain in the UK for 1 year.